Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model

<b>Background</b>: The pharmacokinetic/pharmacodynamic (PK/PD) index of carbapenems that best correlates with in vivo antimicrobial activity is percent time of dosing interval in which free drug concentration remains above MIC (%<i>f</i>T > MIC), while the magnitudes of th...

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Yan Wang, Lanyu Liu, Qiping Wu, Qiufen Yin, Feifan Xie
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Subjects:	pharmacokinetics PK/PD survival meropenem sepsis rat model
Online Access:	https://www.mdpi.com/2079-6382/11/11/1660

Similar Items

Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
by: Yujie Yang, et al.
Published: (2024-08-01)

Prevalence of on time administration of carbapenem and its impact on PK/PD target attainment in hospitalized patients: a multicenter retrospective study
by: Jin Song, et al.
Published: (2025-10-01)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
by: Sergey Zyryanov, et al.
Published: (2023-03-01)

Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing Klebsiella pneumoniae
by: Haoyue Che, et al.
Published: (2025-04-01)

Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective
by: Caterina Bissantz, et al.
Published: (2024-01-01)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Katharina Rox, et al.
Published: (2022-12-01)

Initial Meropenem Plasma Concentration and Its Correlation with Sepsis Mortality: A Real-World Retrospective Study
by: Deng ZW, et al.
Published: (2025-08-01)

Changes of PK/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study
by: Youquan Wang, et al.
Published: (2024-05-01)

Doxorubicin PK/PD modeling in multiple myeloma: towards in silico trials
by: Daniele Andrean, et al.
Published: (2025-03-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
by: Pasquale Maria Berrino, et al.
Published: (2023-08-01)

Optimization of meropenem dosing regimens in critically ill patients with augmented renal clearance
by: Jinfeng Luo, et al.
Published: (2025-05-01)

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
by: Aman P. Singh, et al.
Published: (2019-02-01)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against <i>Acinetobacter baumannii</i> in Patients with Hospital-Acquired Pneumonia
by: Yingjie Zhou, et al.
Published: (2022-05-01)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
by: Stephan Braune, et al.
Published: (2018-01-01)

Meropenem PK/PD Variability and Renal Function: “We Go Together”
by: Jacopo Angelini, et al.
Published: (2023-08-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle
by: Ijaz eAhmad, et al.
Published: (2015-06-01)

Effects of Meropenem on Patients with Ventilator-Induced Pneumonia in Intensive Care Unit
by: Taraneh Naghibi, et al.
Published: (2022-11-01)

Mechanistic insights into synergistic effects using coupled PK-PD modeling
by: Jinzhou Sun, et al.
Published: (2025-05-01)

Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI
by: Shinya Chihara, et al.
Published: (2024-08-01)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
by: Maria Sanz Codina, et al.
Published: (2022-07-01)

PK/PD integration of florfenicol alone and in combination with doxycycline against Riemerella anatipestifer
by: Huilin Zhang, et al.
Published: (2022-09-01)

Population pharmacokinetics of meropenem in critically ill patients
by: Rančić Aleksandar, et al.
Published: (2024-07-01)

Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
by: Guangna Cao, et al.
Published: (2022-03-01)

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
by: Kelly L. Maguigan, et al.
Published: (2021-09-01)

Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations—An Experimental Porcine Study
by: Johanne Gade Lilleøre, et al.
Published: (2023-04-01)

Pharmacokinetics of Macrolide Antibiotics and Transport into the Interstitial Fluid: Comparison among Erythromycin, Clarithromycin, and Azithromycin
by: Shinji Kobuchi, et al.
Published: (2020-04-01)

Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of <i>Neisseria gonorrhoeae</i> Infections
by: Rodrigo Alonso, et al.
Published: (2021-10-01)

Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships
by: Nicolas Simon, et al.
Published: (2025-07-01)

Case report: Successful experience using continuous infusion of meropenem in a geriatric patient with hip fracture complicated by sepsis
by: Assiya Kadralinova, et al.
Published: (2023-04-01)

Pharmacokinetic analysis of meropenem therapeutic drug monitoring data (TDM) in critically ill adult patients
by: I. B. Bondareva, et al.
Published: (2022-03-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
by: Philipp Simon, et al.
Published: (2020-12-01)

PK-PD integration of enrofloxacin and cefquinome alone and in combination against Klebsiella pneumoniae using an in vitro dynamic model
by: Yanzhe Wei, et al.
Published: (2023-10-01)

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

Continuous vs. intermittent meropenem infusion in critically ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
by: Youquan Wang, et al.
Published: (2025-06-01)

Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update
by: Franziska Schneider, et al.
Published: (2022-01-01)

Developing a PK-PD model for propofol in exhaled air and the BIS following fospropofol disodium in beagles
by: Xiaoxiao Li, et al.
Published: (2025-02-01)